PACE-NODES

PACE-NODES is clinical trial to test a rapid form of radiotherapy for prostate cancer.

Disease site: Prostate cancer

Treatment Modality: .

Status: Enrolling participants

What is the study about?

PACE-NODES investigates new ways to give radiotherapy for prostate cancer.

Prostate cancer radiotherapy is normally given over four weeks and targeted to the prostate gland. Giving radiotherapy to lymph glands in the pelvis may help reduce the chance of cancer returning after treatment. Stereotactic body radiotherapy – SBRT – is a new radiotherapy technique which allows treatment to be given over five days.

PACE-NODES uses SBRT to give treatment over five days, either to the prostate on its own or to the prostate and pelvis. Results will be used to improve treatment for people with prostate cancer in future.

Infographic describing PACE-NODES, a trial about radiotherapy for high risk prostate cancer

 

Who is included in the study?

PACE-NODES includes 536 people with prostate cancer that has a high risk of returning after treatment and has not spread elsewhere in the body. Everyone joining the study will start hormone therapy before receiving radiotherapy. Participants are enrolled at hospitals across the UK, Ireland and New Zealand.

What are the study treatments?

Everyone who joins the trial will be in one of two treatment groups: 

  • Prostate SBRT
  • Prostate and pelvis SBRT

Both groups will have five SBRT treatments over two weeks.

Participants have regular check ups during and after their treatment and we collect information about how they are getting on until the study is completed.

Further information for participants

Patient information sheet

Patient information sheet (Large text)

A detailed summary is available on Prostate Cancer UK’s website.

Further information for healthcare professionals

Protocol

Contact details and regulatory information

Chief Investigator: Professor Nicholas van As, The Royal Marsden NHS Foundation Trust

ICR-CTSU scientific lead: Professor Emma Hall

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

Funding: Prostate Cancer UK (PCUK)

Trial identifiers

REC reference: 22/LO/0263

CPMS ID: 307888

NCT05613023

Publications and presentations

There have been no presentations or publications to date.

Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall
New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
See full story
Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story